Stay updated with breaking news from Recursion Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Iambic Therapeutics brings together software engineers and drug-hunting scientists, all sharing the goal of using artificial intelligence to optimize properties of small molecule drugs. The startup will apply its Series B financing to a cancer drug pipeline that includes two candidates on track for the clinic in 2024.
These two next-gen biotechs could be outstanding buys for patient investors.
Yong Rong HK Asset Management Ltd acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,174,200 shares of the company’s stock, valued at approximately $8,772,000. Recursion Pharmaceuticals accounts for 3.8% of Yong Rong HK Asset […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott Larson sold 3,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $7.72, for a total value of $23,160.00. Following the completion of the sale, the chief operating officer now owns 418,782 […]
Even if you're bullish on AI, you may want to think twice about buying shares of these two companies.